logo-loader
viewSareum Holdings PLC

Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial

Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop.

Of particular note was the impact SRA737 had in combination with a common chemotherapy called gemcitabine in patients with anogenital cancer ... ''the trial's been very, very successful indeed'', Mitchell says.

The data's been taken from a phase I/II clinical trial undertaken by Sierra Oncology, which licensed the drug candidate in a deal worth up to US$328.5mln plus royalties.

Quick facts: Sareum Holdings PLC

Price: 0.325 GBX

AIM:SAR
Market: AIM
Market Cap: £9.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Symphony Environmental Technologies has game changing...

Symphony Environmental Technologies PLC (AIM: SYM) CEO Michael Laurier joined Steve Darling from Proactive with news the company has received U.S. Food & Drugs Administration approval or its d2p antimicrobial technology. Laurier discusses what that means for the company and what their...

5 hours, 57 minutes ago

2 min read